Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-03-09
2011-10-25
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387900, C530S391100, C530S391700, C424S130100, C424S133100, C424S134100, C424S178100
Reexamination Certificate
active
08044178
ABSTRACT:
Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
REFERENCES:
patent: 1130094 (2001-09-01), None
patent: 1 152 060 (2001-11-01), None
patent: 1 160 323 (2001-12-01), None
patent: 2 370 571 (2001-11-01), None
patent: 2 378 704 (2002-10-01), None
patent: 89/07947 (1989-09-01), None
patent: 91/09967 (1991-07-01), None
patent: 98/55607 (1998-12-01), None
patent: 02/096948 (2002-12-01), None
patent: 2006/031653 (2003-03-01), None
patent: 03/038098 (2003-05-01), None
patent: 2006/031653 (2006-03-01), None
patent: 2006/042158 (2006-04-01), None
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979).
MacCallum et al. J. Mol. Biol. (1996) 262,732-745.
Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. (2003) BBRC 307, 198-205.
Vajdos et al. (2002) 320, 415-428.
Holm et al. (2007)44, 1075-1084.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Muyldermans and Lauwereys. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. Journal of Molecular Recognition, 1999. vol. 12, pp. 131-140.
Harmsen and Haard. Properties, production and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol., 2007. vol. 77, pp. 13-22.
Forsberg, “Therapy of Human Non-small-cell Lung Carcinoma Using Antibody Targeting of a Modified Superantigen,” British Journal of Cancer, Jul. 6, 2001, vol. 85, No. 1, pp. 129-136.
Shaw, “Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4,” Biochimica Et Biophysica Acta—General Subjects, Dec. 15, 2000, NL, vol. 1524, No. 2-3, pp. 238-246.
Shaw, “Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen,” Biochemical Journal, Apr. 1, 2002, vol. 363, No. 1, pp. 137-145.
Myers, “Targeting Immune Effector Molecules to Human Tumor Cells Through Genetic Delivery of 5T4-specific scFv Fusion Proteins,” Cancer Gene Therapy, Nov. 2002, vol. 9, No. 11, pp. 884-896.
Myers, “Isolation of a cDNA Encoding 5T4 Oncofetal Trophoblast Glycoprotein,” Journal of Biological Chemistry, Mar. 25, 1994, vol. 269, No. 12, pp. 9319-9324.
Woods, “Characterization of the murine 5T4 oncofoetal antigen: A target for immunotherapy in cancer,” Biochemical Journal, Aug. 15, 2002, London, GB, vol. 366, No. 1, pp. 353-365.
Ali et al., “The pattern of expression of the 5T4 oncofoetal antigen on normal, dysplastic and malignant oral mucosa,”Oral Oncology,2001, 37:57-64.
Altschul et al., “Basic Local Alignment Search Tool,”J. Mol. Biol.,1990, 215:403-410.
Angal et al., “A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody,”Molecular Immunology,1993, 30(1):105-108.
Bakker et al., “Receptor Scintigraphy with a Radioiodinated Somatostatin Analogue: Radiolabeling, Purification, Biologic Activity, and In Vivo Application in Animals,”J. Nucl. Med.,1990, 31:1501-1509.
Batzer et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus,”Nucleic Acids Research,1991, 19(18):5081.
Benincosa et al., “Pharmacokinetics and Pharmacodynamics of a Humanized Monoclonal Antibody to Factor IX in Cynomolgus Monkeys,”The Journal of Pharmacology and Experimental Therapeutics,2000, 292(2):810-816.
Boghaert et al., “Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193-N-Acetyl γ Gamma Calicheamicin Dimethyl Hydrazide Targets Lewisγand Eliminates Lewisγ-Positive Human Carcinoma Cells and Xenografts,”Clinical Cancer Research,2004, 10:4538-4549.
Chattopadhyay et al., “Purification and stabilization of99mTc-d,1-HMPAO: Role of organic extractants,”Nuclear Medicine and Biology,2001, 28:741-744.
Cheng et al., “Individualized Patient Dosing in Phase I Clinical Trials: The Role of Escalation with Overdose Control in PNU-214936,”Journal of Clinical Oncology,2004, 22(4):602-609.
Connor et al., “Loss of MHC Class-I Expression in Cervical Carcinomas,”Int. J. Cancer,1990, 46:1029-1034.
Crameri et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution,”Nature,1998, 391:288-291.
Dewanjee et al., “Noninvasive Imaging ofc-mycOncogene Messenger RNA with Indium-111-Antisense Probes in a Mammary Tumor-Bearing Mouse Model,”The Journal of Nuclear Medicine,1994, 35(6):1054-1063.
Forsberg et al., “Identification of Framework Residues in a Secreted Recombinant Antibody Fragment that Control Production Level and Localization inEscherichia coli,” The Journal of Biological Chemistry,1997, 272(19):12430-12436.
Forsberg et al., “Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen,”British Journal of Cancer,2001, 85(1):129-136.
Gilewski et al., “An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel,”Cancer Chemother. Pharmacol.,2000, 46(Suppl):S23-S26.
Goldenberg et al., “The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy,”Critical Review of Oncology/Hematology,2001, 39:195-201.
Green et al., “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,”Nature Genetics,1994, 7:13-21.
Hole et al., “A 72kD trophoblast glycoprotein defined by a monoclonal antibody,”Br. J. Cancer,1988, 57:239-246.
Hole et al., “Isolation and Characterization of 5T4, A Tumour-Associated Antigen,”Int. J. Cancer,1990, 45:179-184.
Houdebine et al., “Antibody manufacture in transgenic animals and comparisons with other system,”Current Opinion in Biotechnology,2002, 13:625-629.
Hoves et al., “The JAM-assay: optimized conditions to determine death-receptor-mediated apoptosis,”Methods,2003, 31:127-134.
Jones et al., “Investigation of expression of 5T4 antigen in cervical cancer,”Br. J. Cancer,1990, 61:96-100.
Jones et al., “Sensitive determination of cell Number using the CyQUANT® cell proliferation assay,”Journal of Immunological Methods,2001, 254:85-98.
Kalofonos et al., “Targeting of Tumours with Murine and Reshaped Human Monoclonal Antibodies Against Placental Alkaline Phosphatase: Immunolocalisation, Pharmacokinetics and Immune Response,”European Journal of Cancer,1994, 30A(12):1842-1850.
Krenning et al., Localisation of Endocrine-Related Tumours with Radioiodinated Analogue of Somatostatin,The Lancet,1989, 242-244.
Liming et al., “Detection of B Lymphoma Cells Undergoing Apoptosis by Annexin-V Assay,”Chin. Med. Sci. J.,2002, 17(1):17-21.
Low et al., “Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,”J. Mol. Biol.,1996, 260:359-368.
Magdelenat et al., “Tumour markers in oncology: past, present and future,”Journal of Immunological Methods,1992, 150:133-143.
Marks et al., “By-Passing Immunization:
Boghaert Erwin R.
Damle Nitin K.
Gill Davinder
Hamann Philip Ross
Khandke Kiran
Gussow Anne M.
Womble Carlyle Sandridge & Rice PLLC
Wyeth LLC
LandOfFree
Anti-5T4 antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-5T4 antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-5T4 antibodies and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4282009